Avidity Biosciences Inc
RNA37.373USD
+1.453+4.05%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
4.50BCap. mercado
PérdidaP/E TTM
Más Datos de Avidity Biosciences Inc Compañía
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.
Información de la empresa
Símbolo de cotizaciónRNA
Nombre de la empresaAvidity Biosciences Inc
Fecha de salida a bolsaJun 12, 2020
Director ejecutivoMs. Sarah Boyce
Número de empleados391
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 12
Dirección10578 Science Center Drive
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92121
Teléfono18584017900
Sitio Webhttps://www.aviditybiosciences.com/
Símbolo de cotizaciónRNA
Fecha de salida a bolsaJun 12, 2020
Director ejecutivoMs. Sarah Boyce
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Sarah Boyce
Ms. Sarah Boyce
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
423.43K
+105.68%
Ms. Teresa Mccarthy
Ms. Teresa Mccarthy
Chief Human Resources Officer
Chief Human Resources Officer
98.09K
+0.99%
Mr. John B. Moriarty
Mr. John B. Moriarty
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
50.00K
+100.00%
Ms. Kathleen P. Gallagher
Ms. Kathleen P. Gallagher
Chief Program Officer
Chief Program Officer
49.64K
-1.80%
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
6.69K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
6.69K
--
Mr. Carsten Boess
Mr. Carsten Boess
Independent Director
Independent Director
6.69K
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Independent Director
Independent Director
6.69K
--
Dr. W. Michael Flanagan, Ph.D.
Dr. W. Michael Flanagan, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Eric B. Mosbrooker
Mr. Eric B. Mosbrooker
Chief Commercial Officer
Chief Commercial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Sarah Boyce
Ms. Sarah Boyce
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
423.43K
+105.68%
Ms. Teresa Mccarthy
Ms. Teresa Mccarthy
Chief Human Resources Officer
Chief Human Resources Officer
98.09K
+0.99%
Mr. John B. Moriarty
Mr. John B. Moriarty
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
50.00K
+100.00%
Ms. Kathleen P. Gallagher
Ms. Kathleen P. Gallagher
Chief Program Officer
Chief Program Officer
49.64K
-1.80%
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
6.69K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
6.69K
--
Desglose de ingresos
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
1.57M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
12.69%
Janus Henderson Investors
9.48%
T. Rowe Price Associates, Inc.
9.30%
Wellington Management Company, LLP
8.03%
The Vanguard Group, Inc.
7.65%
Other
52.85%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
12.69%
Janus Henderson Investors
9.48%
T. Rowe Price Associates, Inc.
9.30%
Wellington Management Company, LLP
8.03%
The Vanguard Group, Inc.
7.65%
Other
52.85%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
47.08%
Investment Advisor
46.95%
Hedge Fund
6.31%
Venture Capital
5.98%
Corporation
4.21%
Research Firm
2.59%
Private Equity
1.94%
Individual Investor
1.01%
Sovereign Wealth Fund
0.60%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
495
141.64M
117.51%
-2.91M
2025Q1
508
142.16M
117.97%
-7.67M
2024Q4
492
135.01M
112.33%
-12.86M
2024Q3
467
132.62M
112.76%
+3.34M
2024Q2
414
118.94M
111.18%
+14.23M
2024Q1
365
96.48M
102.78%
+1.47M
2023Q4
345
83.09M
112.13%
-13.56M
2023Q3
334
86.17M
118.19%
-15.24M
2023Q2
328
86.81M
124.27%
-3.56M
2023Q1
328
80.46M
115.95%
-5.12M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
15.29M
12.69%
-866.01K
-5.36%
Mar 31, 2025
Janus Henderson Investors
11.43M
9.48%
+4.37M
+62.01%
Mar 31, 2025
T. Rowe Price Associates, Inc.
11.21M
9.3%
+289.32K
+2.65%
Mar 31, 2025
Wellington Management Company, LLP
9.68M
8.03%
+1.58M
+19.47%
Mar 31, 2025
The Vanguard Group, Inc.
9.22M
7.65%
-188.71K
-2.01%
Mar 31, 2025
RTW Investments L.P.
8.75M
7.26%
+814.06K
+10.26%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.40M
6.96%
-22.20K
-0.26%
Mar 31, 2025
Avoro Capital Advisors LLC
7.63M
6.33%
+125.00K
+1.67%
Mar 31, 2025
RA Capital Management, LP
6.30M
5.23%
--
--
Mar 31, 2025
Bristol Myers Squibb
5.08M
4.21%
--
--
Sep 30, 2024
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Global X Genomics & Biotechnology ETF
3.64%
ALPS Medical Breakthroughs ETF
2.32%
Tema Neuroscience and Mental Health ETF
1.72%
SPDR S&P Biotech ETF
0.91%
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
Direxion Daily S&P Biotech Bull 3X Shares
0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
0.5%
ProShares Ultra Nasdaq Biotechnology
0.38%
Invesco Nasdaq Biotechnology ETF
0.38%
iShares Biotechnology ETF
0.32%
Ver más
Global X Genomics & Biotechnology ETF
Proporción3.64%
ALPS Medical Breakthroughs ETF
Proporción2.32%
Tema Neuroscience and Mental Health ETF
Proporción1.72%
SPDR S&P Biotech ETF
Proporción0.91%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.8%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0.5%
ProShares Ultra Nasdaq Biotechnology
Proporción0.38%
Invesco Nasdaq Biotechnology ETF
Proporción0.38%
iShares Biotechnology ETF
Proporción0.32%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
